MedTrace Logo

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

NCT02045732 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-01-16

Study results available
· View outcomes & findings →

Summary

PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.

Conditions

Interventions

BIOLOGICAL

PF-06342674 0.25 mg/kg

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

Placebo

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

PF-06342674 1.5 mg/kg

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

PF-06342674 6.0 mg/kg

Bi-Weekly Subcutaneous Injections X 6

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045732 on ClinicalTrials.gov